Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency, part of the Department of War, is soliciting quotes under RFQ HT9402-27-Q-9102 for pharmaceutical agents to be placed on the Uniform Formulary through Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program agreements (UF ADP), with quotes due November 30, 2026. The solicitation carries no set-aside, and the source names no sole-source intent or contract vehicle requirement beyond the BPA and ADP instruments. A pre-quotation teleconference is on November 17, 2026.

Agents under review at the February 3-4, 2027 Pharmacy and Therapeutics Committee meeting are Atebrioz (Skeletal Muscle Relaxants and Combinations), Emcitate (Thyroid and Antithyroid Agents), Hibsago (Hepatitis B Agents), Juvmo (Parkinsons Agents), and Zegfrovy (Lung Cancer, EGFR+ NSCLC). Place of performance is San Antonio, Texas, with pricing applied across Military Treatment Facilities, TRICARE Mail Order Pharmacy, and TRICARE retail network venues.

Manufacturers must submit a separate signed agreement for each agent quoted, an NDC price list in Excel, the Manufacturer Quote Submission Checklist (Appendix 1), and FAR 52.225-6 certification. Offerors must confirm active SAM.gov registration, Trade Agreements Act compliance, and agreement to work with the DoW Prime Vendor Program for MTF and mail order. ADP quotes require the drug to appear on a DoW Retail Refunds Pricing Agreement. Prices must equal or undercut FSS, Big 4, or JNC contract prices, with identical per-unit pricing across all package sizes for each dosage form and strength. Responses to clinical questions in Part 3.4 go by email to the RFQ point of contact in Part 2.3.1.

Price evaluation uses the submitted UF BPA quote or, if none is submitted, the lower of Big 4 or FSS prices as of the first day of the month preceding the P&T meeting for MTF and TMOP venues. Retail venues use the ADP total calculated refund based on most recent annual non-FAMP pricing. The source does not state evaluation weightings.

BPA prices remain valid for 180 days, and manufacturers may decrease prices at any time for at least one year. After two years, price increases are permitted only if FSS prices increase, and they cannot exceed the Big 4 price or the PPI for pharmaceutical preparation manufacturing. ADP refund percentages remain static, though larger refunds may be offered. ADP billing is quarterly, with payment due 70 days from utilization data release. Either party may terminate on 120 days' notice. Manufacturers must notify the Contracting Officer within one business day of transferring assets, and the BPA or ADP transfers automatically to the transferee.

NAICS is 325412, Pharmaceutical Preparation Manufacturing, and PSC is 6505, Drugs and Biologicals.